Respiratory enteric orphan (reo)virus is a promising oncolytic viral candidate. Reoviral anticancer therapy is currently undergoing multiple clinical trials targeting various human cancers; however, there is no effective reoviral inhibitor that can be used to block unwanted reovirus replication during reoviral anticancer therapy.
Methods
Studies were conducted with transformed or normal cells in vitro and in vivo to characterize viral replication in the presence or absence of chemical inhibitors.
Results
We have identified a protease inhibitor that is very effective in the inhibition of viral replication. The dipeptide benzyloxycarbonyl-Phe-Ala-fluoromethyl ketone (Z-FA-FMK) effectively inhibited reovirus replication in a susceptible host and cured cells of a persistent infection with reovirus in vitro. Electron microscopic analysis of Z-FA-FMK-treated cells revealed that internalized reovirus virions, retained in a perinuclear localization, no longer undergo further processing into viral factories following Z-FA-FMK treatment, suggesting that Z-FA-FMK specifically affects a reovirus virion maturation step. Animal studies showed that reovirus infection of Ras oncogenic tumours and host heart tissues is completely blocked by Z-FA-FMK treatment in severe combined immunodeficiency mice.
Conclusions
Z-FA-FMK is a very effective viral inhibitor that can prevent reovirus replication in vitro and reovirus-mediated myocarditis, as well as reovirus-mediated oncolysis, in vivo. A potential application of this drug for inhibition of reovirus infection is suggested.
References
1.
TylerK.L.Mammalian reoviruses. In KnipeD.M., HowleyP.M. (Editors). Fields Virology. Philadelphia: Lippincott Williams & Wilkens2001; pp. 1729–1745.
2.
DuncanM.R., StanishS.M., CoxD.C.Differential sensitivity of normal and transformed human cells to reovirus infection.J Virol1978; 28: 444–449.
3.
HashiroG., LohP.C., YauJ.T.The preferential cytotoxicity of reovirus for certain transformed cell lines.Arch Virol1977; 54: 307–315.
4.
CoffeyM.C., StrongJ.E., ForsythP.A., LeeP.W.Reovirus therapy of tumors with activated Ras pathway.Science1998; 282: 1332–1334.
5.
NormanK.L., LeeP. W.. Not all viruses are bad guys: the case for reovirus in cancer therapy.Drug Discov Today2005; 10: 847–855.
6.
StrongJ.E., CoffeyM.C., TangD., SabininP., LeeP.W.The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.EMBO J1998; 17: 3351–3362.
7.
DuursmaA.M., AgamiR.Ras interference as cancer therapy.Semin Cancer Biol2003; 13: 267–273.
8.
ForsythP., RoldánG., GeorgeD.Phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.Mol Ther2008; 16: 627–632.
9.
BatyC.J., SherryB.Cytopathogenic effect in cardiac myocytes but not in cardiac fibroblasts is correlated with reovirus-induced acute myocarditis.J Virol1993; 67: 6295–6298.
10.
LokenS.D., NormanK., HirasawaK., NodwellM., LesterW.M., DemetrickD.J.Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (Dearing 3) as an anti-cancer biotherapeutic.Cancer Biol Ther2004; 3: 734–738.
11.
SabinA.B.Reoviruses: a new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described.Science1959; 130: 1387–1389.
12.
WeinerH.L., DraynaD., AverillD.R.Jr., FieldsB.N.Molecular basis of reovirus virulence: role of the S1 gene.Proc Natl Acad Sci U S A1977; 74: 5744–5748.
13.
HirasawaK., NishikawaS.G., NormanK.L.Systemic reovirus therapy of metastatic cancer in immune-competent mice.Cancer Res2003; 63: 348–353.
AhmedR., FieldsB.N.Role of the S4 gene in the establishment of persistent reovirus infection in L cells.Cell1982; 28: 605–612.
16.
KimM., EganC., AlainT.Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells.Oncogene2007; 26: 4124–4134.
17.
SmithR.E., ZweerinkH.J., JoklikW.K.Polypeptide components of virions, top component and cores of reovirus type 3.Virology1969; 39: 791–810.
18.
AdachiA., GendelmanH.E., KoenigS.Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.J Virol1986; 59: 284–291.
19.
van MarleG., AntonyJ.M., SilvaC., SullivanA., PowerC.Aberrant cortical neurogenesis in a pediatric neuroAIDS model: neurotrophic effects of growth hormone.AIDS2005; 19: 1781–1791.
20.
RasnickD.Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B.Anal Biochem1985; 149: 461–465.
21.
SchotteP., SchauvliegeR., JanssensS., BeyaertR.The cathepsin B inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide.J Biol Chem2001; 276: 21153–21157.
22.
EbertD.H., DeussingJ., PetersC., DermodyT.S.Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells.J Biol Chem2002; 277: 24609–24617.
23.
EbertD.H., Kopecky-BrombergS.A., DermodyT.S.Cathepsin B is inhibited in mutant cells selected during persistent reovirus infection.J Biol Chem2004; 279: 3837–3851.
24.
LawrenceC.P., KadiogluA., YangA.L., CowardW.R., ChowS.C.The cathepsin B inhibitor, z-FA-FMK, inhibits human T cell proliferation in vitro and modulates host response to pneumococcal infection in vivo.J Immunol2006; 177: 3827–3836.
25.
FieldsB.N., RaineC.S., BaumS.G.Temperature-sensitive mutants of reovirus type 3: defects in viral maturation as studied by immunofluorescence and electron microscopy.Virology1971; 43: 569–578.
26.
RustM.J., LakadamyaliM., ZhangF., ZhuangX.Assembly of endocytic machinery around individual influenza viruses during viral entry.Nat Struct Mol Biol2004; 11: 567–573.
27.
AhmedN.K., MartinL.A., WattsL.M.Peptidyl fluoromethyl ketones as inhibitors of cathepsin B: implication for treatment of rheumatoid arthritis.Biochem Pharmacol1992; 44: 1201–1207.
28.
TanakaY., TanakaR., KawabataT., NoguchiY., HimenoM.Lysosomal cysteine protease, cathepsin B, is targeted to lysosomes by the mannose 6-phosphate-independent pathway in rat hepatocytes: site-specific phosphorylation in oligosaccharides of the proregion.J Biochem2000; 128: 39–48.
29.
SmithJ.A., SchmechelS.C., WilliamsB.R., SilvermanR.H., SchiffL.A.Involvement of the interferon-regulated antiviral proteins PKR and RNase L in reovirus-induced shutoff of cellular translation.J Virol2005; 79: 2240–2250.
30.
NibertM.L., SchiffL.A., FieldsB.N. In KnipeD.M., HowleyP.M. (Editors). Fields Virology. Philadelphia: Lippincott Williams & Wilkens2001; pp. 1557–1596.
31.
HeggieA.D., GaddisL.Effects of viral exposure of the two-cell mouse embryo on cleavage and blastocyst formation in vitro.Pediatr Res1979; 13: 937–941.
32.
PriscottP.K.The growth of reovirus 3 in cultured rat embryos and implications for human reproductive failure.Br J Exp Pathol1983; 64: 467–473.
